Mechanistic modeling of the innate immune responses of the human lung to understand the inter-individual heterogeneity of COVID-19 pneumonia

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 5R01HL169974-02

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2023.0
    2027.0
  • Known Financial Commitments (USD)

    $731,876
  • Funder

    National Institutes of Health (NIH)
  • Principal Investigator

    PROFESSOR REINHARD LAUBENBACHER
  • Research Location

    United States of America
  • Lead Research Institution

    UNIVERSITY OF FLORIDA
  • Research Priority Alignment

    N/A
  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Disease pathogenesis

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

PROJECT SUMMARY/ABSTRACT A key feature of the COVID-19 infection is the vast inter-individual heterogeneity in the severity of the infection. The complex biological mechanisms that underlie this variability remain mostly obscure. We propose to provide a mechanistic understanding of this susceptibility by leveraging 3 key innovations: First, we have developed a 3-dimensional lung culture system that allows for detailed interrogation of the early events in SARS-CoV-2 infection. Second, we have established an animal model of COVID-19 in mice transgenic for the human ACE2 receptor in our facility. Third, we have built a multi-scale mathematical model of lung infection in COVID-19, that we now seek to expand and personalize to individual hosts. We have two Aims in this project: In Aim 1, we will validate, expand, and personalize our existing multi-scale model, using an unbiased approach to identify and test hypotheses relating to susceptibility to severe COVID-19, and in Aim 2 we will test a specific hypothesis regarding the mechanism of the observed inter-individual heterogeneity in COVID-19 severity, namely that it is, in part, mediated by divergent activation of the mTOR pathway in type I alveolar epithelial cells. If successful, this project will identify the biological basis of the immune pathways that result in heterogeneous outcome of COVID-19, paving the way for personalized, host-specific interventions to improve the outcome of the infection.